Report Code: A12598 | Pages: NA | ||
Tables: NA | Charts: NA |
|
Anesthetic drugs are used while performing surgical procedures to control blood pressure, breathing, pain, heart rate, rhythm, and blood flow. Inhalational anesthesia is a chemical compound with anesthetic characteristics and is mainly used for sedation purposes and the induction of general anesthesia. These drugs are administered by the facemask and a tracheal tube attached to the vaporizer and another delivery system. Among inhalation anesthesia, isoflurane is the oldest and popular drug that is very efficient in low doses. As it eliminates risks and passed via the lungs to reduce hospital care costs, it preferred in case of impaired hepatic. It is anticipated to have a positive impact on market growth in coming years due to an increase in number of accidents and emergency cases.
COVID-19 Impact analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the inhalational anesthesia drugs market.
Top Impacting Factors
Market Trends
New product launches to flourish the market
In January 2019, Sandoz, a Novartis division, has launched Desflurane, Liquid for Inhalation, the first generic of Suprane in the U.S., as an inhalation agent. It is used for induction and maintenance of anesthesia for inpatient and outpatient surgery in adults, and for maintenance of anesthesia for inpatient and outpatient surgery in pediatric patients.
Key Benefits of the Report
Questions answered in the inhalational anesthesia drugs Report
Inhalational Anesthesia Drugs Market Report Highlights
Aspects | Details |
---|---|
By Product Type |
|
By Application |
|
By End User |
|
By Region |
|
Key Market Players | Piramal Enterprises Limited, Baxter International, AbbVie Inc., Fresenius Kabi AG, Troikaa Pharmaceuticals Ltd, Jiangsu Hengrui Medicine Co. Ltd., Lunan Pharmaceutical Group Co. Ltd., Hikima Pharmaceuticals PLC, Halocarbon Products Corporation |
Loading Table Of Content...
Start reading.
This Report and over 71,295+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time for readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save the time of readers